Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 4/20 | 0.77 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.46 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13220588 | 0.87 | CDK9 (0.57) | CDK9CDK2CCNT1CCNA2CCNA1 | |
| SCHEMBL4033318 | 0.87 | CDK9 (1.00) | CDK9CDK2CCNT1CCNA2CCNA1 | |
| SCHEMBL13202856 | 0.85 | CDK9 (0.77) | CDK9CDK2CCNT1CCNA2CCNA1 | |
| SCHEMBL13202858 | 0.85 | CDK9 (0.81) | CDK9CDK2CCNT1CCNA2CCNA1 | |
| SCHEMBL13220777 | 0.82 | CDK9 (0.53) | CDK9CDK2CCNT1CCNA2CCNA1 | |
| SCHEMBL13202860 | 0.82 | CDK9 (0.72) | CDK9CDK2CCNT1CCNA2CCNA1 | |
| SCHEMBL13202950 | 0.81 | CDK9 (0.72) | CDK9CDK2CCNT1CCNA2CCNA1 | |
| SCHEMBL117207 | 0.81 | CDK9 (0.72) | CDK9CDK2CCNT1CCNA2CCNA1 | |
| SCHEMBL14311712 | 0.81 | CDK9 (0.70) | CDK9CDK2CCNT1CCNA2CCNA1 | |
| SCHEMBL13220662 | 0.81 | CDK9 (0.55) | CDK9CDK2CCNT1CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772241-B2 | Variolin derivatives and their use as antitumor agents | PHARMA MAR S.A. (ES) | 2010-08-10 | — | — | US | disclosed |
| US-20090197901-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | PHARMA MAR, S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| US-7495000-B2 | Variolin derivatives and their use as antitumor agents | PHARMA MAR, S.A. (ES) | 2009-02-24 | — | — | US | disclosed |
| US-7320981-B2 | Antitumor agents | PHARMA MAR, S.A. (ES) | 2008-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197901-A1 | VARIOLIN DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS | CBR3, CCNL2, HRH3 | CDK9 1364/4885CDK2 48/4885CCNT1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.